Member Info for Scinv_temp

You can ask Phoebe Buffay for all I care. Constant mentioning of WB is a guarantee that one is talking with an "inbestor" of the garden variety. Don't worry moni, all they need to do is stay focused on growing the business, and as far as we know from what they told us, that's exactly what they they are doing, no need for weird made up scenarios, just patience and vigilance

It would mean they have nothing better to do with the cash. From my view if this happened I would take the opportunity to reduce my position.

Buying back or issuing dividents would be a moronic thing to do, trying to create the expectation that it will happen is a close second

Do I really have to? Not going through that again. If you didn't know that then you are not much of an investor, are you? Hopefully the covid crowd will disappear soon, back to your day jobs :)

In case you didn't get it, no one has an obligation to reference what you can easily find with a google search.
Many companies, including most of the major pharmas, have a p38 inhibitor "on the shelf" (as is the vernacular) with at least phase 1 data that mostly concerns safety. With that said, all of them have failed on efficacy for what the campanies was testing then for. That sort of thing matters in this business because even if OO has found a new target population for it, there is no one stopping everyone else from doing the same, unless they get an orphan drug designation, which they won't (they haven't even applied because it would make no sense).

OO has nailed it with the challenge studies, I truly beleive that (though I could still be wrong). In my humble opinion, they have nothing that isn't related to that that has real value. The sooner we get rid of all the nonsense the better. My opinion and nothing more than that. Have a nice evening.

*get rid of it

Everyone and their mother has a p38 inhibitor, most of them at later stages of development than POLB. I hope they get rid of poolberg at any price. I don't mind that OO used to spread their bets, but now now it is clear that only hvivo related business has real value. Gettif of it and move on

Lmao

Billy

Assuming your average is £1, the only thing certain is that you can recover about 20% of your initial investment now. A year from now you may be able to recover 0-5% or maybe 50% or more. We are all guessing here and I for one have never pretended to be any sort of expert in finance. Don't get carried away by people here fooling themselves they understand the science (or the finance part for the vast majority here).

The idea that you will most likely eventually recover more of your investment is fantasy. Ghia doesn't know that, nobody does. Maybe you decide to wait it out and there is nothing wrong with that, but in my view don't do it with the false assumption that recovery is more likely than further decline.

The idea that when someone that takes notes from a conference and posts them on a public forum, it is then inappropriate for someone else to post them on another public forum is ridiculous. Lmao.

So... what did he say then?

It doesn't say "up to", it says "at".

The trial will not be resumed, it was closed a few months after pausing it. They are just catching up with sample processing and data analysis.

Also beware of the "Marsden-speak", the viral load in samples was in the original protocol, the fact that they did post-hoc analysis means the endpoint as prespecified in the protocol did not show satisfactory results so they had to data dredge again. It could be that it just showed something with hrv in particular, which in itself is an interesting result which is definitely actionable, but what worries me most is the day 7 part. Was it just this particular day that showed statistically significant reaults? If that's the case, regulatory authorities will laugh this out, as a curve of efficacy is expected towards approval. To be fair they say nothing about approval, it's all towards informing future trials, as the company says in the RNS.

Similarly, the secondary bacterial infection datapoint in all likelyhood was just a numerical difference of no statistical significance, otherwise they would be saying otherwise.

"Viral clearance from the lower respiratory tract
Sputum samples were collected where possible at study visits conducted during and after the 14-day dosing period. Assessment of viral clearance focused on the most frequently detected virus, human rhinovirus (HRV), which accounted for approximately 50% of infections. The results suggest that HRV was cleared more rapidly in patients treated with SNG001 than placebo with a statistically significant difference in the proportion of patients with detectable HRV in sputum at Day 7 (post hoc analysis).

Markers associated with secondary bacterial infections
In COPD exacerbations, sputum purulence and elevated levels of serum C-reactive protein (CRP) are associated with the presence of bacteria in the lower respiratory tract. In the second week of treatment, a greater proportion of patients in the placebo group had purulent sputum or elevated serum CRP."

Frieled

"Avoid at all costs. Do not recommend. The chips were cold. Zero stars."

Tell me you are the below avaerage fool who discovered the stock market during covid, without telling me you are the average fool who discovered the stock market during covid.

Lmao

No worries, nothing you need to do. Once they finish the process, from your end, your shares will just be renamed to HVO, you'll get an email from your broker explaining the name change and that's it.

@shorteverything

For your continued service

https://discountcode.dailymail.co.uk/mcdonalds

Why is it that every stock forum has a a village idiot that is all doom and gloom and another announcing a takeover every other day?

At least on 2-3 occasions management has said that scaling activities should be straightforward. Though there is always a chance the client asked for those timelines specifically, I hope to see them increasing capacity in the next few months

Open Orphan plc (http://www.openorphan.com) (AIM: ORPH), a rapidly growing
specialist contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge clinical
trials, announces that hVIVO (http://www.hvivo.com) , a subsidiary of Open
Orphan, has signed a £10.4m contract with an existing top 5 global
pharmaceutical client to manufacture a new batch of H1N1 influenza challenge
virus, leveraging off an existing in-house generated challenge model, and to
conduct a human challenge trial to test the client's antiviral product.



hVIVO has world-leading expertise in challenge agent manufacture, with the
ability to manufacture specific subtypes of viruses, as well as unrivalled
experience in conducting challenge studies. Since the COVID-19 pandemic, the
Company has seen an increase in the number of clients looking to test their
vaccines and antivirals against specific subtypes of viruses that are
circulating in the population or that have the potential to be widely spread.
As a result, there is a greater interest in end-to-end human challenge
contracts such as this, that include a novel challenge agent manufacture and a
challenge study.



The study will evaluate the efficacy profile of the antiviral against the
specific influenza subtype, generating data quickly and efficiently. This is
the third human challenge contract signed with this client, highlighting the
Company's world leading expertise and the clear benefits of human challenge
trials to Big Pharma's drug development process.



Good Manufacturing Practice ("GMP") compliant virus manufacturing activities
will commence immediately and are expected to complete by Q2 2023. Once
completed, hVIVO will conduct a Phase 2a double-blinded placebo-controlled
human challenge study which is expected to be completed by Q4 2023. hVIVO will
recruit healthy volunteers via the Company's dedicated volunteer recruitment
arm, FluCamp (http://www.flucamp.com) . The majority of revenue from the
contract is expected to be recognised during 2023.

...

I guess this is what happens when one realises they are incompetent as traders, they spread nonsense on public forums. The village drunk is just entertainment really.

So a dodgy oil exploration co and a garbage plant-meat co lifted during the covid madness with expanding losses as apparently good ol SPAM canned pork is taking away market share from them. I guess I was spot on lmao